1. China's medical insurance bureau recently stated clearly that the future of quantity procurement can promote the scale development of the generic drug industry. After the pilot expansion, 25 pharmaceuticals will cover all regions of the country, and the requirements for product quality, capacity supply and cost control will be higher. Enterprises will face greater competitive pressure, which will help promote the optimization and restructuring of the industry and gradually change. The scale of the industry is small and the quality is low, which promotes the scale, intensification and modernization of the industry. (But it is too fast, many SMEs have no time to prepare, this piece also requires the government to point out a living path.)
2. Saving national medical insurance, resources can cover generic drugs widely, and covering new special drugs has more spare capacity. Of course, this is not enough, and commercial medical insurance needs to be developed together. The patient's accessibility to generic drugs has been greatly increased, and there is basically no problem with the protection. After a round of rectification and baptism, the pharmaceutical companies will be relatively comfortable. The interest of doctors is gradually becoming more standardized, and more measures are taken to increase the corresponding income.
3. Look at the current foreign generics pattern, although it is not the same as China's basic situation, background and development process.
In 2018, 90% of the US prescriptions were generic; it is reported that a total of 5.2 billion generic prescriptions were issued, corresponding to a 22% generic amount. Generics have saved a lot of money, estimated at $292.6 billion in 2018.
2018 US top 10 generic drugs to save on medical expenses (in order: atorvastatin, ondansetron, omeprazole, rosuvastatin, gabapentin, aripiprazole, amlodipine, simvastatin , montelukast sodium, quetiapine)
